There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
All
Ages:
21 years and below
Trial Updated:
04/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Medulloblastoma
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
All
Ages:
22 years and below
Trial Updated:
04/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Neuroblastoma
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
All
Ages:
31 years and below
Trial Updated:
04/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Neuroblastoma
Register for Updates
FIT Families Multicomponent Obesity Intervention for African American Adolescents
NCT04974554
Recruiting
Obesity is one of the most prevalent medical problems facing children and adolescents today, particularly among African American adolescents where the rate is alarmingly high. This study will test the effectiveness of FIT Families, a multicomponent family-based behavioral intervention that is culturally tailored to meet the unique needs of African American adolescents with obesity and their caregivers, against a credible attention control condition. This study has considerable public health rele... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Division of Global and Community Health, Charleston, South Carolina
Conditions: Obesity, Childhood, Metabolic Syndrome
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Alcohol Associated Hepatitis
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Neuroblastoma
Register for Updates
A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
NCT05865535
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in metastatic cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: MUSC Hollings Cancer Center, Charleston, South Carolina
Conditions: Cachexia
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
NCT05616221
Recruiting
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Register for Updates
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
NCT05492188
Recruiting
The purpose of the second part of the study is to examine the effect of reflex training in the leg to decrease neuropathic pain. For this, the researchers are recruiting 15 individuals with neuropathic pain due to spinal cord injury to participate in the reflex training procedure. The study involves approximately 50 visits with a total study duration of about 6.5 months (3 months for baseline and training phases followed by 1 month and 3 month follow-up visits).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Spinal Cord Injuries, Neuropathic Pain, Neurological Injury, Pain
Register for Updates
Neuromodulation and Dynamic Balance in Stroke
NCT05135533
Recruiting
Portable Neuromodulation Stimulator (PoNS) is non-invasive stimulation device placed on the tongue to stimulate those brain regions understood to be important for maintaining balance. This research study aims to collect evidence that PoNS therapy along with balance training improves postural and walking stability post-stroke.
Gender:
All
Ages:
Between 22 years and 85 years
Trial Updated:
04/02/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Stroke
Register for Updates
Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals
NCT04058561
Recruiting
A hospital-based cluster stratified randomization control study will be conducted to investigate spinal growth in Early Onset Scoliosis patients between 5 and 9 years of age. Patients must have a major coronal curve measuring over 50 degrees and be undergoing Magnetically Controlled Growing Rod treatment. We will be studying 6-week lengthening intervals compared to 16-week lengthening intervals on spinal growth within 3 years.
Gender:
All
Ages:
Between 5 years and 9 years
Trial Updated:
04/01/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Early-Onset Scoliosis Deformity of Spine
Register for Updates